Novel anticancer agents show promise to control tumor growth in nearly every cancer type

Reviewed by James Ives, M.Psych. (Editor)Jul 9 2019

A gene called MYC has become one of the hottest targets for cancer researchers around the world. MYC is known to drive tumor growth in nearly all cancer types - but successfully targeting the gene has proven to be a challenge. One that has been baffling researchers for more than three decades.

Now, researchers at Purdue University have discovered a novel set of MYC promoter G-quadruplex stabilizers that have demonstrated anticancer activity in human cancer cell cultures. The discovery is published in the July 8 edition of the Journal of the American Chemical Society.

We are striving to discover effective anticancer agents. The ability to incorporate MYC promoter G-quadruplex stabilizing activity into existing topoisomerase I inhibitors has shown promise in making them more potent as anticancer agents and in making cancer cells less likely to become resistant to them."

Mark Cushman, distinguished professor of medicinal chemistry, Purdue's College of Pharmacy, lead resaercher

The Purdue team discovered potential anticancer agents that target the MYC promoter G-quadruplex and downregulate the expression of the MYC oncogene, which is overexpressed in cancer and is associated with almost all aspects of cancer development. The work has been supported by the National Cancer Institute and the National Institutes of Health.

Cushman, whose cancer research work contributed to his election as a fellow of the National Academy of Inventors, said they discovered a novel class of indenoisoquinoline MYC promoter G-quadruplex stabilizers in collaboration with Danzhou Yang. Some of them also inhibit topoisomerase I, an enzyme that facilitates DNA replication and is produced in greater amounts in cancer cells.

"Targeting promoter G-quadruplexes offers a relatively new and exciting strategy to inhibit the critical oncogene expression in cancer cells," said Yang, the Martha and Fred Borch Chair of Cancer Therapeutics in Purdue's College of Pharmacy, who led the research with Cushman. "We hope to combine the potency of the DNA-targeted drugs and selectivity of molecular-targeted approaches for new cancer therapeutics."

Yang and Cushman, both members of the Purdue University Center for Cancer Research, said the agents they discovered could be used in helping to treat nearly every type of cancer. Some of the technology from their work has been licensed to Gibson Oncology LLC through the Purdue Research Foundation Office of Technology Commercialization.

Some of the work Cushman and his team previously developed led to three anticancer agents that are in clinical trials. The MYC innovation will greatly enhance interest in these anticancer agents within the scientific community and will also contribute to the understanding of how they work.

The work aligns with Purdue's Giant Leaps celebration, acknowledging the university's global advancements in health as part of Purdue's 150th anniversary. This is one of the four themes of the yearlong celebration's Ideas Festival, designed to showcase Purdue as an intellectual center solving real-world issues.